NCT05128929View on ClinicalTrials.gov

Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

September 21, 2023

Study Completion Date

September 29, 2023

Conditions
Pulmonary Hypertension
Interventions
DRUG

Hymecromone (H01)

800 mg oral H01 two times a day (total dose: 1600 mg/day).

DRUG

Placebo

Oral tablet placebo (inactive ingredients) two times a day.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER